Graft-versus-host disease

HORSHAM, PA — The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) recently approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients …